# **Special Issue**

# Functional Nanocarrier Technology to Deliver siRNA for Cancer Therapy

## Message from the Guest Editors

Nucleic acid medicines, including antisense oligonucleotides, small interfering RNA (siRNA), aptamers, and locked nucleic acids, have the potential to the rapeutically regulate gene expressions. In recent years, new drugs for genetic diseases have been developed and are attracting a great deal of attention. However, these strategies are limited to treating localized diseases so far. That is why further development of drug delivery systems (DDSs) is essential for the clinical application of nucleic acid medicine to apply cancer treatment. To address this challenging issue, we focus on development of DDSs to deliver siRNA for cancer therapy, and we will clarify the usefulness of cancer treatment by target gene regulation using nucleic acid medicine designed by functional nanocarrier. This Special Issue will highlight the development of DDSs using functional nanocarriers to deliver siRNA for cancer therapy. We also expect to discuss the possibility of developing novel nanocarrier design with added value to conventional technology.

### **Guest Editors**

Prof. Dr. Daisuke Ishibashi

Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma Jonanku, Fukuoka, Japan

#### Dr. Mai Hazekawa

Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma Jonanku, Fukuoka, Japan

### Deadline for manuscript submissions

closed (10 March 2022)



# **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



mdpi.com/si/79811

Pharmaceutics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics





an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).

